This is a working overview of Regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
=== Metabolism === Clobazam has five major metabolites: N-desmethylclobazam, 4'-Hydroxy-N-desmethylclobazam, the former of which is activeN-desmethylclobazam-3',4'-dihydrodiol and 4'-Hydroxyclobazam The demethylation is facilitated by CYP2C19, CYP3A4, and CYP2B6 and the 4'-Hydroxyclobazam by CYP2C18 and CYP2C19. N-desmethylclobazam is further metabolized and cleared through hydroxylation by the enzyme CYP2C19. 9-Hydroxy-N-desmethylclobazam is one of the hydroxylated products of this process. While the parent drug clobazam is highly active, its primary metabolite, N-desmethylclobazam, is also pharmacologically active and possesses a significantly longer half-life (compared to clobazam's 36–42 hours). 9-Hydroxy-N-desmethylclobazam functions mostly as a pathway toward drug clearance. The half-life is approximately 36 to 42 hours for clobazam and 71 to 82 hours for N-desmethylclobazam.
Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, paclitaxel stabilizes the microtubule polymer and protects it from disassembly. Chromosomes are thus unable to achieve a metaphase spindle configuration. This blocks the progression of mitosis and prolonged activation of the mitotic checkpoint triggers apoptosis or reversion to the G0-phase of the cell cycle without cell division. The ability of paclitaxel to inhibit spindle function is generally attributed to its suppression of microtubule dynamics, but other studies have demonstrated that suppression of dynamics occurs at concentrations lower than those needed to block mitosis. At the higher therapeutic concentrations, paclitaxel appears to suppress microtubule detachment from centrosomes, a process normally activated during mitosis. Paclitaxel binds to the beta-tubulin subunits of microtubules.
=== Investment === Investment in dedicated UK AI companies rebounded to £2.9 billion in 2024, surpassing the previous record of £2.4 billion set in 2022 and recovering strongly from a trough of £1.5 billion in 2023. The average deal size rose to approximately £5.9 million in 2024, compared to £4.6 million in 2022. International investors, including Microsoft, Nvidia, and SoftBank, continue to provide the largest investment contributions. In 2024, there were 51 AI-related inward investment projects into the UK, representing over £15 billion in capital investment and expected to create more than 6,500 jobs. These were dominated by infrastructure investments from Amazon, Google, CoreWeave, and Vantage Data Centres. Despite this growth, qualitative research conducted for the Sector Study identified a persistent "scale-up gap": the UK is described as "very good at the start phase, but [at] the scale up phase (beyond Series A), there's a missing piece there". More than half of dedicated AI companies identified in 2024 are at the seed stage of development, showing a healthy start-up scene, but investors cited a lack of larger-scale growth capital, risk aversion among existing UK investors, and insufficient uptake of pension fund investment in venture capital as key structural barriers.
Sources: en.wikipedia.org
While meeting with British prime minister Keir Starmer in February 2025, Trump accepted a request from King Charles III for a state visit in the U.K.; both Trump and Starmer praised the U.S.–U.K. "Special Relationship". The state visit occurred between September 16–18, 2025. Relations became strained in March 2026 due to Starmer's refusal to join the U.S.–Israeli strikes on Iran during the 2026 Iran war or support the U.S. naval blockade of Iran, prompting Trump to repeatedly condemn the prime minister. King Charles III undertook a state visit to the United States between April 27–30, 2026 and addressed Congress, aimed partly at alleviating these tensions.
The process of acute inflammation is initiated by resident immune cells already present in the involved tissue, mainly resident macrophages, dendritic cells, histiocytes, Kupffer cells and mast cells. These cells possess surface receptors known as pattern recognition receptors (PRRs), which recognize (i.e., bind) two subclasses of molecules: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). PAMPs are compounds that are associated with various pathogens, but which are distinguishable from host molecules. DAMPs are compounds that are associated with host-related injury and cell damage. At the onset of an infection, burn, or other injuries, these cells undergo activation (one of the PRRs recognize a PAMP or DAMP) and release inflammatory mediators responsible for the clinical signs of inflammation. Vasodilation and its resulting increased blood flow causes the redness (rubor) and increased heat (calor). Increased permeability of the blood vessels results in an exudation (leakage) of plasma proteins and fluid into the tissue (edema), which manifests itself as swelling (tumor). Some of the released mediators such as bradykinin increase the sensitivity to pain (hyperalgesia, dolor). The mediator molecules also alter the blood vessels to permit the migration of leukocytes, mainly neutrophils and macrophages, to flow out of the blood vessels (extravasation) and into the tissue. The neutrophils migrate along a chemotactic gradient created by the local cells to reach the site of injury.
The enzyme is a cytochrome P450 protein containing heme, isolated from peppermint. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
The Cossack Khmelnytsky Uprising of 1648–1657 engulfed the south-eastern regions of the Polish crown; its long-term effects were disastrous for the Commonwealth. The first liberum veto (a parliamentary device that allowed any member of the Sejm to dissolve a current session immediately) was exercised by a deputy in 1652. This practice would eventually weaken Poland's central government critically. In the Treaty of Pereyaslav (1654), the Ukrainian rebels declared themselves subjects of the Tsar of Russia. The Second Northern War raged through the core Polish lands in 1655–1660; it included a brutal and devastating invasion of Poland referred to as the Swedish Deluge. The war ended in 1660 with the Treaty of Oliva, which resulted in the loss of some of Poland's northern possessions. In 1657 the Treaty of Bromberg established the independence of the Duchy of Prussia. The Commonwealth forces did well in the Russo-Polish War (1654–1667), but the result was the permanent division of Ukraine between Poland and Russia, as agreed to in the Truce of Andrusovo (1667). Towards the end of the war, the Lubomirski's rebellion, a major magnate revolt against the king, destabilized and weakened the country. The large-scale slave raids of the Crimean Tatars also had highly deleterious effects on the Polish economy. Merkuriusz Polski, the first Polish newspaper, was published in 1661. In 1668, grief-stricken at the recent death of his wife and frustrated by the disastrous political setbacks of his reign, John II Casimir abdicated the throne and fled to France.[z]
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.